Anixa Biosciences CAR-T Co-Inventor to Present at South Carolina Research Retreat on Ovarian Cancer Therapy

Jose Conejo-Garcia, M.D., Ph.D., Professor of Immunology at Duke University School of Medicine and co-inventor of Anixa Biosciences’ CAR-T technology, will deliver a keynote presentation at the South Carolina Clinical & Translational Research Institute 2026 Retreat on March 6, 2026. The retreat’s theme is ‘Cell-Based Therapies from Discovery to Translation.’ Conejo-Garcia is expected to discuss Anixa’s ongoing Phase 1 clinical trial of liraltagene autoleucel (lira-cel), an FSHR-targeted CAR-T therapy for recurrent ovarian cancer. The therapy was first discovered at The Wistar Institute.

The clinical study is enrolling women with recurrent ovarian cancer who have progressed after at least two prior therapies. Anixa’s therapeutic portfolio centers on lira-cel, an ovarian cancer immunotherapy being developed in collaboration with Moffitt Cancer Center. The technology uses a novel approach known as chimeric endocrine receptor-T cell (CER-T) technology. This platform is differentiated from other cell therapies because the natural ligand of the FSHR receptor, follicle-stimulating hormone (FSH), binds to the FSHR receptor on the tumor cell instead of an antibody fragment.

Moffitt Cancer Center is recognized as a world leader in cancer immunotherapy, pioneering next-generation cell therapies including CAR-T and tumor-infiltrating lymphocytes (TILs). Anixa’s business model involves partnering with renowned research institutions for development and commercialization. Beyond its CAR-T program, the company’s vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast and ovarian cancer. These vaccines target ‘retired’ proteins expressed in certain cancers. Cleveland Clinic developed the breast and ovarian cancer vaccines and exclusively licensed them to Anixa, entitling the clinic to royalties and commercialization revenues. The company is also exploring additional cancer vaccines for high-incidence malignancies in lung, colon, and prostate. More information about Anixa Biosciences can be found at https://www.anixa.com.

The announcement was distributed via BioMedWire, a specialized communications platform focused on biotechnology and life sciences sectors, which is part of the Dynamic Brand Portfolio at IBN. BioMedWire provides services including wire distribution, editorial syndication, press release enhancement, and social media distribution. Full terms of use and disclaimers for content provided by BioMedWire are available at https://www.BioMedWire.com/Disclaimer.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Anixa Biosciences CAR-T Co-Inventor to Present at South Carolina Research Retreat on Ovarian Cancer Therapy.

The post Anixa Biosciences CAR-T Co-Inventor to Present at South Carolina Research Retreat on Ovarian Cancer Therapy appeared first on citybuzz.